Brief: Kazia Therapeutics Announces The Filing Of Provisional Patent For Novel Strategy, Supported By Preclinical Data, To Prevent Metastatic Recurrence In Triple-Negative Breast Cancer
28/07/2026 12:50
BRIEF-Kazia Therapeutics Announces The Filing Of Provisional Patent For Novel Strategy, Supported By Preclinical Data, To Prevent Metastatic Recurrence In Triple-Negative Breast Cancer July 28 (Reuters) - Kazia Therapeutics Ltd KZIA.O:
KAZIA THERAPEUTICS ANNOUNCES THE FILING OF PROVISIONAL PATENT FOR NOVEL STRATEGY, SUPPORTED BY PRECLINICAL DATA, TO PREVENT METASTATIC RECURRENCE IN TRIPLE-NEGATIVE BREAST CANCER
Source text: ID:nGNX84gxcK
Further company coverage: KZIA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering